Mineralocorticoid receptor antagonists (MRAs) reduce mortality and morbidity in patients with heart failure with reduced ejection frac tion, particularly if administered early fol lowing myocardial infarction. They are also likely to improve outcomes in some patients with heart failure and preserved ejection fraction (diastolic dysfunction) (1) . Cardio protection in heart failure is independent of any blood pressure effects of MRAs. How ever, the detailed mechanisms underlying the cardioprotective effects of MRAs and even the cellular locus have been elusive. New research by Oakley et al. (2) focused on cardiomyocytes demonstrates the importance of the balance between MR and glucocorticoid receptor (GR) in determining whether dam aged cardiomyocytes die or survive.
Aldosterone is generally considered the main ligand for MRs. However, MRAs dis place the glucocorticoid cortisol from the heart in humans, not aldosterone (3). Thus, in cardiomyocytes (which lack the glucocorticoid inactivating enzyme 11hydroxysteroid dehydrogenase2), cortisol-or its mouse equivalent, corticosterone-binds to the higheraffinity MR as well as GR. Although both receptors have similar DNA binding specificity, they regulate distinct gene sets and frequently act in opposition (4, 5) . The relative roles of MRs and GRs in mediating the cardiac effects of cortisol have been dif ficult to disentangle. Knockout of one re ceptor leaves the other cortisolsignaling pathway intact but unopposed. In a previ ous study, Oakley et al. (6) described mice lacking GR in cardiomyocytes (cardioGRKO) and their premature death from heart failure. This new study asked whether spontaneous disease in cardioGRKO mice resulted from loss of the GR or unopposed MR action. It is prob ably both. They showed that simultaneous knockout of the MR (cardioGRMRdKO) al leviated the left ventricular (LV) dysfunction of cardioGRKO and postponed the onset of overt heart failure by several months. This occurred despite similar or worsened inflam mation and cardiomyocyte hypertrophy in cardioGRMRdKO mice. Reexpression of MR in cardioGRMRdKO mice partially reversed the cardiac benefits of knocking out the MR (Fig. 1) .
Key to the findings was the serendipi tous choice of the cardiomyocytespecific myosin heavy chain (MHC) promoter-Cre recombinase transgene to knock out GR (and MR) in cardiomyocytes. Several groups have reported that MHCCre introduces breaks into cellular DNA through Cre recombinase cleavage at cryptic LoxP sites. In the Oakley et al. study, Dmd mRNA (which encodes dystrophin) was decreased in hearts of cardioGRKO, cardioMRKO, and cardioGRMRdKO mice. This finding is consistent with the agerelated loss of dystrophin in hearts of MHCCre mice (7) and progressive accumulation of DNA damage in cardiomyocytes due to the MHC Cre transgene. A strength of the study was the inclusion of MHCCre mice as a control in some of the experiments, though not in the measurement of Dmd mRNA. A different line of cardiomyocyte GR knockout mice in which Cre is transiently expressed in cardio myocytes during development does not de velop spontaneous heart failure (8), so the heart failure seen in cardioGRKO mice de pends upon the cardiomyocyte injury intro duced by Cre recombinase.
DNA damage is proinflammatory and can be catastrophic in cardiomyocytes, which have limited regenerative capacity. Oxida tive stress, which is increased in heart failure, also causes DNA damage. Repair of damaged DNA allows cell survival, but if the damage is excessive or cannot be repaired, then cell death is triggered. The new study by Oakley et al. (2) suggests that MR and GR are important determinants of the outcome in cardio myocytes. How? GRmediated control of cardio myocyte inflammation is not critical for cardiomyocyte survival, because inflamma tory markers were more highly expressed in cardioGRMRdKO hearts. Similarly, mark ers of cardiomyocyte hypertrophy were as high (or higher) in cardioGRMRdKO hearts as in cardioGRKO hearts. MR deficiency in cardiomyocytes, therefore, does not prevent either inflammation or cardiomyocyte hyper trophy. Does the GR/MR balance affect the decision between cell death and survival? The differential gene analyses certainly sup port this notion: Expression of genes in cell survival pathways was decreased, whereas that of genes in cell death pathways was increased in cardioGRKO hearts, compared to cardio GRMRdKO mice. Moreover, cardioGRKO hearts fared worse than MHCCre hearts, consistent with an antiapoptotic role for GR in cardiomyocytes. Conversely, MR defi ciency may protect against apoptosis trig gered by DNA damage (or its consequences): LV function was preserved in 6monthold cardioMRKO mice, an age at which MHCCre mice show reduced fractional shortening, which is evidence of LV dysfunction and early heart failure (Fig. 1) . The cell death/ survival decisions may be directly regulated by GR and MR or may be indirect and related to differential ion channel remodeling fol lowing GR and/or MR activation. Both receptors regulate Ca 2+ currents in cardio myocytes (as well as in the brain) by distinct mechanisms and in a complex, interdepen dent manner. Context is critical in deter mining the outcomes of cortisol action, such as when the membrane potential is shifted from its resting level (a key issue in excitable cells like cardiomyocytes or neurons) or when tissue damage occurs. In the brain, MR acti vation by cortisol shapes the early response to stress (akin to a "proinflammatory" phase), with GR activation being important for adap tion and recovery (an "antiinflammatory" phase) (4) . Similarly, by acting through both the MR and GR, cortisol controls the spec trum of the cardiomyocyte response to dam age. Intriguingly, spironolactone, an MRA in wide clinical use, ameliorates cardiotox icity during combined chemo and radio therapy in a rat model (9) and may attenuate chemotherapyinduced LV dysfunction in breast cancer patients (10) Fig. 1 . The balance between MR and GR in cardiomyocytes determines the outcome of DNA damage upon heart function. Cortisol signaling through MR and GR determines the outcome of DNA damage in cardiomyocytes. Removal of the GR leaves MR signaling unopposed, resulting in progressive loss of cardiomyocytes, LV dysfunction, and heart failure. DNA damage causes oxidative stress, impaired Ca 2+ signaling, decreased cell survival, and increased cell death through apoptosis and necrosis. Unopposed GR signaling in the absence of MR preserves LV function in the face of DNA damage. In mice lacking GR, deletion of MR delays the onset of LV dysfunction and heart failure.
